Home » Newsletters » BioWorld Science

BioWorld Science

June 12, 2002

View Archived Issues

SignalGene and Novuspharma enter collaboration and option agreement for SG-292

Novel prenyltranferase inhibitors useful in cancer therapy identified at Merck

New 5-HT6 antagonists for obesity and CNS disorders

Lilly presents novel glutamate receptor function enhancers

Protein kinase inhibitors in development at Morphochem

Nucleoside analogues and their use in viral infections and cancer

COX-2 inhibitors claimed by researchers at Temple University

CCR1 antagonists in early development at Pfizer

Isradipine safely reduces cocaine-related effects

Carrier-mediated active transport is responsible for hepatic uptake of Z-335

Alexion reviews third-quarter highlights

Positive phase III results announced for ophthalmic implant for diabetic macular edema

Roche Diagnostics acquires HPV patent portfolio from Institut Pasteur

GSK to evaluate BioVex's ImmunoVEX vaccine platform

ActivX and Kyorin enter drug discovery collaboration in type 2 diabetes

Clinical results for oral tridentate iron chelator ICL-670 discussed in Florence

Adenovirus-mediated ribonucleotide reductase gene therapy inhibits human colon cancer growth

TranzVector-mediated delivery of human IFNbeta gene effective in human tumor xenograft model

GVAX cancer vaccines highlighted at the ASGT meeting

Antiproliferative sulindac derivative targets the Ras pathway

New antimicrobial peptide may be useful for burn and wound infections

Adherex Technologies updates Exherin progress

Lexicon Genetics identifies new target for obesity drug development

Promising results reported for Trisenox in myelodysplastic syndromes

Transkaryotic Therapies broadens intellectual property in Gaucher's and Fabry's diseases

Wyeth discontinues development of PTP-112

Merck & Co. to refile Arcoxia NDA in second half of 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...